达格列净对利拉鲁肽治疗后超重/肥胖2型糖尿病患者的疗效

陈晓军; 曾建

PDF(597 KB)

武警医学 ›› 2020, Vol. 31 ›› Issue (7) : 557-560.

论著

达格列净对利拉鲁肽治疗后超重/肥胖2型糖尿病患者的疗效

陈晓军, 曾建

作者信息 +

Efficacy of dapagliflozin for overweight/obese patients with type 2 diabetes after liraglutide treatment

CHEN Xiaojun, ZENG Jian

Author information +

文章历史 +

摘要

目的观察达格列净对利拉鲁肽治疗12周后超重/肥胖2型糖尿病患者(type 2 diabetic mellitus, T2DM)的疗效。方法选取93例经利拉鲁肽治疗刚满12周的超重/肥胖T2DM患者,按1∶1随机分为利拉鲁肽(liraglutide,Lir)组46例和达格列净(dapagliflozin,Dap)组47例。Lir组继续应用利拉鲁肽,Dap组换用达格列净,继续治疗12周。比较两组治疗前后血糖、体重、腰围、血压变化。结果治疗12周后,两组的血糖、体重、腰围、血压均较治疗前下降(P<0.01),其中空腹血糖(fasting blood glucose,FBP)[(1.0±0.6)vs(0.8±0.5)] mmol/L,餐后2 h血糖(2 hours postprandial blood glucose,2hBG)[(1.3±0.8)vs(1.4±0.9)]mmol/L,糖化血红蛋白(glycated hemoglobin,HbA₁c)[(1.0±0.5)vs(0.9±0.6)]%,体重[(1.5±1.4)vs(1.0±1.2)]kg,体重指数(body mass index,BMI)[(0.7±0.6)vs(0.5±0.4)]kg/m²,收缩压[(5.0±3.0)vs(5.0±2.5)]mmHg,舒张压[(3.0±1.0)vs(3.0±1.2)]mmHg,下降幅度无统计学差异(P＞0.05)。但Dap组腰围下降少于Lir组(P<0.01)。结论对利拉鲁肽治疗后超重/肥胖的T2DM患者,换用达格列净,除腰围下降较少外,降糖、减重、降压的效果与继续原药治疗相同。

Abstract

Objective To investigate the efficacy of dapagliflozin for overweight/obese patients with type 2 diabetes after 12 weeks of treatment with liraglutide.Methods A total of 93 overweight/obese type 2 diabetes patients who had been treated with liraglutide for just 12 weeks were randomly divided into the liraglutide group (n=46) and the dapagliflozin group (n=47).Patients in the liraglutide group continued to take liraglutide, while the dapagliflozin group switched to dapagliflozin. The treatment lasted 12 weeks in both groups before the changes of blood glucose, weight, waist circumference and blood pressure were compared.Results The blood glucose, weight, waist circumference and blood pressure were significantly lower in both groups after treatment(P<0.01). The extent to which fasting blood glucose [(1.0±0.6)vs(0.8±0.5)] mmol/L, 2-hour postprandial blood glucose[(1.3±0.8)vs(1.4±0.9)] mmol/L, glycated hemoglobin [(1.0±0.5)vs(0.9±0.6)]%, body weight [(1.5±1.4)vs(1.0±1.2)] kg, body mass index[(0.7±0.6)vs(0.5±0.4)] kg/m², systolic blood pressure[(5.0±3.0)vs(5.0±2.5)]mmHg, and diastolic blood pressure[(3.0±1.0)vs(3.0±1.2)]mmHg (P>0.05) decreased was not statistically different between the two groups. However, the waist circumference of the dapagliflozin group decreased less significantly [(1.9±1.3)vs(0.9±0.8)] cm(P<0.01).Conclusions For overweight/obese patients with type 2 diabetes after liraglutide treatment, switching to dapagliflozin will have the same effect as continued treatment with liraglutide on blood glucose, weight, and blood pressure except for the waist circumference.

导出引用

陈晓军, 曾建. 达格列净对利拉鲁肽治疗后超重/肥胖2型糖尿病患者的疗效[J]. 武警医学. 2020, 31(7): 557-560

CHEN Xiaojun, ZENG Jian. Efficacy of dapagliflozin for overweight/obese patients with type 2 diabetes after liraglutide treatment[J]. Medical Journal of the Chinese People Armed Police Forces. 2020, 31(7): 557-560

中图分类号： R587.1

参考文献

[1] Duan C M, Wan T F, Wang Y, et al. Cardiovascular outcomes of liraglutide in patients with type 2 diabetes-a systematic review and meta-analysis[J].Medicine,2019, 98(46):e17860-17866.
[2] Wharton S, Kuk J L, Luszczynski M, et al. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery[J]. Clin Obes, 2019, 9(4): e12323-12329.
[3] Wiviott S D, Raz I, Bonaca M P, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4):347-357.
[4] Cai X, Ji L, Chen Y, et al. Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: a meta-analysis[J]. J Diabetes Investig, 2017, 8(4):510-517.
[5] Sohita D. Dapagliflozin: a review in type 2 diabetes[J]. Drugs, 2019,79(10):1135-1146.
[6] Mazidi M, Rezaie P, Gao H K, et al. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22528 patients[J]. J Am Heart Assoc,2017,6(6): 1-23.
[7] Mirabelli M, Chiefari E, Caroleo P,et al. Long-term effectiveness of liraglutide for weight management and glycemic control in type 2 diabetes[J]. Int J Environ Res Public Health, 2019, 17(1): 207-218.
[8] Zhao X, Huang K, Zheng M, et al. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials[J]. BMC EndocrDisord, 2019, 19(1):4-18.
[9] Adams J M, Pei H, Sandoval D A, et al. Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons[J]. Diabetes,2018, 67(8):1538-1548.
[10] Ishii S, Nagai Y, Sada Y, et al. Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes: a prospective case series[J]. J Clin Med Res, 2019, 11(3): 219-224.
[11] Schork A, Saynisch J, Vosseler A,et al. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy[J]. Cardiovasc Diabetol,2019,18(1):46-58.
[12] Fadini G P, Bonora B M, Zatti G,et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial[J]. Cardiovasc Diabetol, 2017,16(1): 42-52.